Astellas seeks FDA approval for Tarceva
The company submitted a supplemental new drug application (sNDA) based on the data from randomized, controlled Phase 3 EURTAC trial conducted in patients with EGFR triggering mutation-positive advanced
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.